Leuprolide
- Generic Name
- Leuprolide
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N16O12
- CAS Number
- 53714-56-0
- Unique Ingredient Identifier
- EFY6W0M8TG
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...
- Associated Conditions
- Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- Palliative Treatment
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT02083185
Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation
- Conditions
- Interventions
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Michigan Reproductive Medicine
- Target Recruit Count
- 38
- Registration Number
- NCT02069808
- Locations
- 🇺🇸
Michigan Reproductive Medicine, Bloomfield Hills, Michigan, United States
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
- Conditions
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 17
- Registration Number
- NCT02064036
- Locations
- 🇺🇸
UC Davis Sacramento Cancer Center Dept of Radiation Oncology, Sacramento, California, United States
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 160
- Registration Number
- NCT01989780
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT01933022
- Locations
- 🇳🇱
Site NL31005 St. Antonius ziekenhuis, Nieuwegein, Netherlands
🇳🇱Site NL31004 Radboudumc, Nijmegen, Netherlands
🇳🇱Site NL31001 Canisius-Wilhelmina Ziekenhuis, Nijmegen, Netherlands
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
- Conditions
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 912
- Registration Number
- NCT01767090
- Locations
- 🇵🇱
Site: 1505, Bialystok, Poland
🇵🇱Site: 1508, Lublin, Poland
🇵🇱Site: 1509, Warsaw, Poland
Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
- Conditions
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2016-12-05
- Target Recruit Count
- 33
- Registration Number
- NCT01750398
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT01547299
Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 487
- Registration Number
- NCT01458301
A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis
- Conditions
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 397
- Registration Number
- NCT01452685
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.